Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

>

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideli
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... fruit fly and roundworm,s functional genomic elements: DNA sequences in ... are turned on and off at various times in different ... Human Genome Project, the genomes of the fruit fly, ... are powerful models for understanding human biology and disease, ...
... 22, 2010 Pathfinder LLC, a private biotechnology company ... cell damage ("Pathfinder"), and SyntheMed, Inc. (OTC Bulletin Board: ... the "Company"), today announced that they have entered into ... renamed  "Pathfinder Cell Therapy, Inc." and the combined company ...
... Inc. (Nasdaq: NVAX ) and scientists at ... Trudy Morrison, published in the January 2011 issue of ... novel virus-like particle (VLP) vaccine candidate against respiratory syncytial ...  This vaccine candidate has been created with technology that ...
Cached Biology Technology:Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 2Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 3Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 2Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 3Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 5Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 6NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 4
(Date:4/17/2014)... way the immune system may fight cancers and viral ... cells to treat illness. , The research, in mice, ... "neighborhood police" specialized squads of defenders that patrol ... entire city, the body. , Scientists at Washington University ... the liver, skin and uterus each has dedicated immune ...
(Date:4/17/2014)... of our ideas about domestication derive from Charles ... by British animal-breeding practices during the 19th century, ... improvement. , It is from Darwin that ... of captive animals from wild species and total ... But animal management in this industrial setting has ...
(Date:4/16/2014)... Florida State University researchers have identified a new ... bone density and muscle mass with obesity. , "It ... were the better your bones would be because the ... Hazel Stiebeling Professor of Nutrition at Florida State. "But, ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2
... A new study from Boston University School of Medicine ... (iPS) cells in an experimental model were not rejected ... published online in Cell Stem Cell , demonstrates ... types that could offer treatment for a wide range ...
... Research Institute (TSRI) have been awarded approximately $1.2 million ... the National Institutes of Health to identify, test and ... of diseases, including rheumatoid arthritis, heart disease and several ... director in TSRI,s Translational Research Institute, and Peter S. ...
... German . , The detector combines near-unity ... very low error rate. The results have been published ... and reliable single-photon detectors are among the most sought-after ... yet reached maturity for practical application. Physicist Dr. Wolfram ...
Cached Biology News:BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection 2Grant to fund development of drug candidates for rheumatoid arthritis, neurodegenerative disorders 2Quantum communication: Each photon counts 2